You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(01877.HK)2024年度業績:營收增長30%至19.48億元,淨虧損大幅收窄約44%
格隆匯 03-27 22:26

格隆匯3月27日丨君實生物(01877.HK)公佈年度業績,截至2024年12月31日,報告期內集團收入總額約人民幣19.48億元,較2023年同期增加約30%,主要由於藥品收入的增加,其中:核心產品拓益®(特瑞普利單抗)國內銷售收入約爲人民幣15.01億元,較2023年同期增加約66%。

報告期內集團研發開支總額約人民幣12.75億元,較2023年同期減少約34%。研發開支減少主要由於集團實施成本控制政策,努力優化資源配置,聚焦於更有潛力的研發管綫。此外,核心產品拓益?的多項臨牀試驗相繼達到主要研究終點亦促進研發開支自然下降。

報告期內公司擁有人應佔虧損減少至人民幣12.82億元,較2023年同期減少約人民幣9.99億元或約44%。

 截至2024年12月31日,集團銀行結餘及現金和金融產品餘額合計約人民幣29.17億元,資金狀況相對充裕,可支持集團的發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account